OXiGENE, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today announced that it has entered into a definitive agreement with certain institutional investors to sell 6,578,945 shares of its Common Stock and separate series of warrants to purchase Common Stock in a private placement.
- 24/7 Technology,Internet,Bio Patent and Intellectual Property News & Information Service
-
SUBSCRIBE TO FEED
- Who are patent attorneys?
- What are patents, and how long are they in force?
- Valuing patents
- Steps in the Patent Process
- Intellectual Property and patents thereof
- History of Patents and Patent Law
- Copyrights & Copyright Law History
- Historically Famous U.S. patents
- Comparing Patents & Copyrights
- Applying for a Patent? Follow these steps
-
Articles
Leave Your Comment
You must be logged in to post a comment.